目的:观察阿帕替尼用于铂耐药复发上皮性卵巢癌患者二线以上化疗后维持治疗的临床疗效和安全性。方法:36例确诊为铂耐药复发上皮性卵巢癌的患者,接受非铂类二线以上药物化疗至少4疗程,并已获得临床缓解或稳定后,给予口服阿帕替尼维持治...目的:观察阿帕替尼用于铂耐药复发上皮性卵巢癌患者二线以上化疗后维持治疗的临床疗效和安全性。方法:36例确诊为铂耐药复发上皮性卵巢癌的患者,接受非铂类二线以上药物化疗至少4疗程,并已获得临床缓解或稳定后,给予口服阿帕替尼维持治疗,初始剂量均为500 mg,qd,直至疾病进展或毒副作用不能耐受。采用实体瘤疗效评价标准(response evaluation criteria in solid tumors,RECIST)1.0版和CA125、HE4两个指标综合评价疗效,按照美国国家癌症研究院(National Cancer Institute,NCI)的常见毒性标准3.0版对药物的不良反应进行分级。结果:36例患者客观缓解率(objective response rate,ORR)为52.2%,疾病控制率(disease control rate,DCR)为69.4%。在19例获得部分缓解的患者中,中位缓解持续时间为8.1(2.5~23.1)个月,其中12例患者(63.2%)的缓解持续时间≥6个月,6例获得疾病稳定评价的患者中,中位稳定持续时间为5.85(3.2~9.3)个月,其中3例患者(50%)的疾病稳定状态持续时间≥6个月。阿帕替尼每天250 mg剂量,患者可以很好耐受。结论:阿帕替尼对铂耐药复发上皮性卵巢癌患者二线以上化疗后的维持治疗是安全、有效的。展开更多
AIM: To assess the efficacy and safety of the combination of pegylated liposomal doxorubicin(PLD) and carboplatin in patients with recurrent epithelial ovarian carcinoma(ROC), following disease progression on single a...AIM: To assess the efficacy and safety of the combination of pegylated liposomal doxorubicin(PLD) and carboplatin in patients with recurrent epithelial ovarian carcinoma(ROC), following disease progression on single agent PLD. METHODS: An analysis of the medical records of 10 patients with ROC, treated in our institution with a combination of PLD and carboplatin following progression on single-agent PLD therapy was performed. The median age was 59.1 years(range, 45 to 77 years). All diagnoses were histological-proven. Eight of the 10 patients were platinum-resistant. Following disease progression on single-agent PLD treatment, carboplatin area under the curve(AUC)-5 was added to PLD in all 10 patients. In order to assess disease status, Ca-125 was assessed before each PLD/carboplatin treatment. Relative changes in Ca-125 values were calculated, and response defined as a greater than 50% reduction in Ca-125 from baseline. Radiographic studies were reevaluated and responses to therapy based on com-puter tomography(CT) scans carried out on a regular basis every 2-3 mo in each patient. Statistical analysis was performed using SPSS(V19).RESULTS: A median of 10 cycles(range, 2-26) of the carboplatin-PLD combination was given. Of the 10 treated patients, 6 had > 50% reduction in Ca-125 levels from baseline, 4 of these had a partial response according to Response Evaluation Criteria in Solid Tumors(RECIST) criteria, and the other 2 patients had no measurable disease. In a further 2 patients with a best response of disease stabilization and < 50% reduction of Ca-125 levels, one had progression of disease after 26 cycles, and the second progressed with brain metastases following 12 cycles. Seven of the eight patients who were platinum-resistant showed evidence of clinical benefit on carboplatin-PLD combination therapy; 5 of these had > 50% reduction in Ca-125 level, 4 also showed a partial response on CT scan. The treatment was generally well-tolerated by the patients. CONCLUSION: Addition of carboplatin to PLD, after dise展开更多
文摘目的:观察阿帕替尼用于铂耐药复发上皮性卵巢癌患者二线以上化疗后维持治疗的临床疗效和安全性。方法:36例确诊为铂耐药复发上皮性卵巢癌的患者,接受非铂类二线以上药物化疗至少4疗程,并已获得临床缓解或稳定后,给予口服阿帕替尼维持治疗,初始剂量均为500 mg,qd,直至疾病进展或毒副作用不能耐受。采用实体瘤疗效评价标准(response evaluation criteria in solid tumors,RECIST)1.0版和CA125、HE4两个指标综合评价疗效,按照美国国家癌症研究院(National Cancer Institute,NCI)的常见毒性标准3.0版对药物的不良反应进行分级。结果:36例患者客观缓解率(objective response rate,ORR)为52.2%,疾病控制率(disease control rate,DCR)为69.4%。在19例获得部分缓解的患者中,中位缓解持续时间为8.1(2.5~23.1)个月,其中12例患者(63.2%)的缓解持续时间≥6个月,6例获得疾病稳定评价的患者中,中位稳定持续时间为5.85(3.2~9.3)个月,其中3例患者(50%)的疾病稳定状态持续时间≥6个月。阿帕替尼每天250 mg剂量,患者可以很好耐受。结论:阿帕替尼对铂耐药复发上皮性卵巢癌患者二线以上化疗后的维持治疗是安全、有效的。
文摘AIM: To assess the efficacy and safety of the combination of pegylated liposomal doxorubicin(PLD) and carboplatin in patients with recurrent epithelial ovarian carcinoma(ROC), following disease progression on single agent PLD. METHODS: An analysis of the medical records of 10 patients with ROC, treated in our institution with a combination of PLD and carboplatin following progression on single-agent PLD therapy was performed. The median age was 59.1 years(range, 45 to 77 years). All diagnoses were histological-proven. Eight of the 10 patients were platinum-resistant. Following disease progression on single-agent PLD treatment, carboplatin area under the curve(AUC)-5 was added to PLD in all 10 patients. In order to assess disease status, Ca-125 was assessed before each PLD/carboplatin treatment. Relative changes in Ca-125 values were calculated, and response defined as a greater than 50% reduction in Ca-125 from baseline. Radiographic studies were reevaluated and responses to therapy based on com-puter tomography(CT) scans carried out on a regular basis every 2-3 mo in each patient. Statistical analysis was performed using SPSS(V19).RESULTS: A median of 10 cycles(range, 2-26) of the carboplatin-PLD combination was given. Of the 10 treated patients, 6 had > 50% reduction in Ca-125 levels from baseline, 4 of these had a partial response according to Response Evaluation Criteria in Solid Tumors(RECIST) criteria, and the other 2 patients had no measurable disease. In a further 2 patients with a best response of disease stabilization and < 50% reduction of Ca-125 levels, one had progression of disease after 26 cycles, and the second progressed with brain metastases following 12 cycles. Seven of the eight patients who were platinum-resistant showed evidence of clinical benefit on carboplatin-PLD combination therapy; 5 of these had > 50% reduction in Ca-125 level, 4 also showed a partial response on CT scan. The treatment was generally well-tolerated by the patients. CONCLUSION: Addition of carboplatin to PLD, after dise
